Page 82 - Read Online
P. 82
Page 8 of 11 Nguyen et al. J Transl Genet Genom 2018;2:19 I http://dx.doi.org/10.20517/jtgg.2018.20
Figure 3. Androgen pathway in triple negative breast cancers. Bicalutamide acts as an inhibitor competing with DHT on cytoplasmic
AR. Abiraterone acetate inhibits CYP17, thus reducing testosterone synthesis in adrenal tissue. DHT: dihydrotestosterone; AR: androgen
receptors; CYP17: cytochrome P450 17 alpha-hydroxylase; ACTH: adrenocorticotropic hormone; DHEA: dehydroepiandrosterone
